Conditions: Melanoma Metastatic
Keywords: Metastatic Melanoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 8
Healthy volunteers: no

Brief summary:
To determine whether Interleukin-2 at the dose and schedule will help to increase tumor shrinkage

Detailed description:
In this phase II trial, the previously described IL-2 schedule (daily IL-2 for 5 days (per week) every 3 weeks) will be tested in a larger cohort of patients with melanoma to attempt to determine the response rate, median duration of response, and median survival. The dose intensity of this schedule would allow a patient treated on this regimen to achieve the target threshold (\> 1440 million IU/m2/year).

Arms:
arm 1: Interleukin-2 will be used in this group

Interventions: intervention 1: Interleukin-2
Intervention descriptions: intervention 1: Interleukin-2

Protocol document: